Business context and reporting period
The supplied filing is Catalyst Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016, filed May 5, 2016—not a filing identified as Gyre Therapeutics, Inc. The filing describes a clinical-stage biotechnology company developing engineered protease medicines, primarily for hemophilia and other bleeding and inflammatory conditions. It had no products approved for commercial sale and no product-sales revenue.
Pipeline highlighted: CB 813d, a Factor VIIa candidate, had completed a Phase 1 trial; CB 2679d/ISU 304, a Factor IX candidate, was in advanced preclinical development. The company had deferred further work on Factor Xa and an anti-C3 candidate to focus resources on its lead programs.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Contract revenue | $109,000 | $672,000; down 84% |
| Research and development expense | $2.286 million | $1.383 million; up 65% |
| General and administrative expense | $2.395 million | $2.321 million; up 3% |
| Total operating expenses | $4.681 million | $3.704 million; up 26% |
| Operating loss | $4.572 million | $3.032 million |
| Interest and other income, net | $980,000 | $174,000 |
| Net loss | $3.592 million | $2.858 million |
| Net loss per share, basic and diluted | $0.31 | $7.67 |
| Cash used in operating activities | $4.744 million | $2.980 million |
Amounts are in U.S. dollars. Revenue was collaboration revenue, not product sales. Gross profit and gross margin are not separately reported; a product margin is not meaningful for this pre-commercial business.
- At March 31, 2016, cash and cash equivalents were $20.580 million and short-term investments were $7.087 million, totaling about $27.7 million of cash and short-term investments. Restricted cash was a further $31.113 million current and $125,000 noncurrent, principally collateral for the notes.
- Total assets were $61.543 million; total liabilities were $33.554 million; stockholders’ equity was $27.989 million. Current liabilities included $30.936 million of redeemable convertible notes. The notes do not bear interest and are secured by escrowed restricted cash; maturity is February 19, 2018, unless redeemed or converted earlier.
- Investing activities used $3.772 million, mainly from purchases of investments. Financing cash flow was zero: $2.807 million of released restricted cash was offset by note-redemption payments of the same amount.
- The company reported an accumulated deficit of $134.629 million and had 11,430,108 common shares outstanding at March 31, 2016.
Material changes versus the prior comparable period
- Contract revenue fell primarily because Pfizer terminated its collaboration effective June 1, 2015; the Pfizer-related deferred revenue had been fully recognized by then. ISU Abxis accounted for all Q1 2016 contract revenue.
- R&D expense increased with higher staffing and research activity, preclinical vendor and lab costs, and manufacturing costs for CB 813d. G&A was broadly stable.
- Operating loss widened by $1.540 million. Net loss widened by $734,000 despite higher interest and other income, which included a substantial noncash fair-value gain on the notes’ derivative liability.
- Operating cash use increased by $1.764 million year over year. Cash and cash equivalents decreased from $29.096 million at year-end 2015 to $20.580 million; short-term investments increased from $3.402 million to $7.087 million.
- The derivative liability declined from $1.156 million to $196,000, including an $875,000 fair-value gain and an $85,000 gain on extinguishment of notes.
Outlook, risks, and unusual items
- Management said existing capital resources were expected to fund projected operating requirements for at least 12 months, while cautioning that assumptions could prove wrong. It expected significant expenses and increasing operating losses for at least the next several years.
- Management expected R&D spending to increase in coming quarters. The company planned to advance CB 813d toward an efficacy trial and stated that collaborator ISU Abxis was expected to initiate a Phase 1 trial of CB 2679d/ISU 304 in 2016. These are forward-looking statements, not assurances.
- Key development risks include clinical failure, delays, manufacturing and regulatory hurdles, and safety concerns. The filing notes an unconfirmed assay result for a possible non-neutralizing anti-drug antibody in one CB 813d trial participant; follow-up confirmatory testing was planned. A treatment-related neutralizing immune response in later trials could halt development.
- The company may need additional equity, debt, or collaboration funding. It warned that financing may be unavailable or dilutive and that insufficient funding could force delays, spending cuts, or suspension of programs. A shelf registration effective April 28, 2016 permitted offerings of up to $50 million; a sales agreement also permitted up to $6.5 million of common-stock sales.
- Other disclosed obligations and contingencies include $1.414 million of operating lease payments and potential ISU Abxis milestone payments of up to $2.0 million, excluded from the contractual-obligations table because achievement and timing were not considered probable and estimable. The company reported no material legal proceedings and no off-balance-sheet arrangements.
- Unusual accounting item: the $980,000 of interest and other income materially benefited from a noncash change in fair value of the embedded note conversion derivative; it should not be treated as recurring operating revenue.
Important facts for investors to verify
- Confirm the issuer: the provided filing is for Catalyst Biosciences, Inc., although the request metadata names Gyre Therapeutics, Inc.
- Verify the availability and permitted use of cash: $31.113 million of current restricted cash primarily collateralized the redeemable convertible notes and was not ordinary operating liquidity.
- Track the 12-month liquidity assertion against quarterly cash burn, future R&D spending, and any financing or partnership activity.
- Check clinical progress and safety follow-up for CB 813d, and whether the anticipated CB 2679d/ISU 304 trial began as stated.
- Assess the sustainability of collaboration revenue after Pfizer’s termination and the extent to which reported earnings depend on noncash fair-value changes.